Wang Jiayu

2 clinical trials · Sponsor

Record	Firm	Date
Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer (NCT06653972)	Wang Jiayu	2024-11-01
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer (NCT06539559)	Wang Jiayu	2024-08-01

Every clearance here is in the API, with alerts when new ones post.